Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Part of paid clinical trials in Clearwater, Florida.

Sponsor
Esperion Therapeutics, Inc.
Study ID
NCT02991118
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bempedoic acid — DRUG
    bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
  • placebo — DRUG
    Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

Study Details

The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.

Key Dates

Start date
Nov 18, 2016
Status verified
Apr 2020
Primary completion
Aug 22, 2018
Completion
Aug 22, 2018

Study Design

Enrollment
779 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: bempedoic acid
    bempedoic acid 180 mg/day
  • Placebo Comparator: Placebo
    Placebo control

Primary Outcome Measure

Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) [ Time Frame: Baseline; Week 12 ]

Locations (2)

FacilityCityStateZIPSite coordinators
-ClearwaterFlorida--
-GeorgetownTexas--

Related Studies